Unlike protective antibody titers (anti-VZV, anti-TT, and anti-PCP) that returned to baseline levels at the end of the study, stable suppression of anti-Dsg-1 antibodies and anti-Dsg-3 antibodies to lower levels than before treatment were observed during the 10 weeks of efgartigimod-free follow-up (Figure 1D). The gene discussed is DSG3; the disease is pneumocystosis.